{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:57:25Z","timestamp":1694397445386},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1097\/fpc.0000000000000262","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T21:04:37Z","timestamp":1481749477000},"page":"70-77","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger"],"prefix":"10.1097","volume":"27","author":[{"given":"Roc\u00edo","family":"Guti\u00e9rrez-C\u00edvicos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Torres-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 J.","family":"Sanchez-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Espa\u00f1ol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Consuegra-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Perez-Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda D.","family":"Guti\u00e9rrez-Meca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Conesa-Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-4-20210213","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2012.41.7527","article-title":"Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?","volume":"31","author":"Cabanillas","year":"2013","journal-title":"J Clin Oncol"},{"key":"R3-4-20210213","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/asheducation-2007.1.216","article-title":"Clinical features, prognosis and treatment of follicular lymphoma","volume":"2007","author":"Salles","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R4-4-20210213","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"R5-4-20210213","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/1078-0432.CCR-10-1292","article-title":"Interindividual variability of response to rituximab: from biological origins to individualized therapies","volume":"17","author":"Cartron","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R6-4-20210213","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"R7-4-20210213","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"R8-4-20210213","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"R9-4-20210213","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines","volume":"204","author":"Flieger","year":"2000","journal-title":"Cell Immunol"},{"key":"R10-4-20210213","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration\u2013effect relationship","volume":"64","author":"Dall\u2019Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"R11-4-20210213","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"R12-4-20210213","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R13-4-20210213","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","article-title":"The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy","volume":"13","author":"Zhou","year":"2008","journal-title":"Oncologist"},{"key":"R14-4-20210213","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-05-0554","article-title":"Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin\u2019s lymphomas","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R15-4-20210213","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"R16-4-20210213","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1158\/1078-0432.CCR-08-0745","article-title":"A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma","volume":"14","author":"Racila","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R17-4-20210213","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"R18-4-20210213","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"R19-4-20210213","first-page":"198","article-title":"Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma","volume":"123","author":"Zhang","year":"2010","journal-title":"Chin Med J"},{"key":"R20-4-20210213","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2011-05-351411","article-title":"Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism","volume":"118","author":"Veeramani","year":"2011","journal-title":"Blood"},{"key":"R21-4-20210213","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4149\/neo_2011_03_263","article-title":"Fc\u03b3RIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy","volume":"58","author":"Prochazka","year":"2011","journal-title":"Neoplasma"},{"key":"R22-4-20210213","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"R23-4-20210213","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cancergencyto.2008.02.001","article-title":"FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients","volume":"183","author":"Paiva","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"R24-4-20210213","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","article-title":"Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis","volume":"79","author":"Morales-Lara","year":"2012","journal-title":"Joint Bone Spine"},{"key":"R25-4-20210213","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00277-013-1864-4","article-title":"Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas","volume":"93","author":"Heredia-Galvez","year":"2014","journal-title":"Ann Hematol"},{"key":"R26-4-20210213","doi-asserted-by":"crossref","first-page":"e90090","DOI":"10.1371\/journal.pone.0090090","article-title":"Association of the polymorphisms in the Fas\/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"R27-4-20210213","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Gu\u00e9rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"key":"R28-4-20210213","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2005.02635.x","article-title":"Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn\u2019s disease","volume":"22","author":"Hlavaty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-4-20210213","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.1002\/ajh.24354","article-title":"A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients","volume":"91","author":"Guti\u00e9rrez-C\u00edvicos","year":"2016","journal-title":"Am J Hematol"},{"key":"R30-4-20210213","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mc.20814","article-title":"Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure","volume":"51","author":"Ruiz-Cosano","year":"2012","journal-title":"Mol Carcinog"},{"key":"R31-4-20210213","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R32-4-20210213","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"20","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R33-4-20210213","first-page":"17","article-title":"Pharmacogenetics: implementing personalized medicine","volume":"6","author":"Mini","year":"2009","journal-title":"Clin Cases Miner Bone Metab"},{"key":"R34-4-20210213","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-2-50","article-title":"New targets for the treatment of follicular lymphoma","volume":"2","author":"Tageja","year":"2009","journal-title":"J Hematol Oncol"},{"key":"R35-4-20210213","first-page":"23","article-title":"Apoptosis, c\u00e1ncer Co","volume":"1","author":"Pazo Cid","year":"2012","journal-title":"Rev Int Grupos Invest Oncol"},{"key":"R36-4-20210213","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1038\/sj.onc.1207104","article-title":"Monoclonal antibody therapeutics and apoptosis","volume":"22","author":"Ludwig","year":"2003","journal-title":"Oncogene"},{"key":"R37-4-20210213","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.4049\/jimmunol.156.8.2693","article-title":"Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis","volume":"156","author":"Eischen","year":"1996","journal-title":"J Immunol"},{"key":"R38-4-20210213","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin\u2019s lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica"},{"key":"R39-4-20210213","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"R40-4-20210213","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival: a study from the groupe d\u2019etude des lymphomes de l\u2019adulte","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol"},{"key":"R41-4-20210213","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/asheducation-2013.1.561","article-title":"Dissecting follicular lymphoma: high versus low risk","volume":"2013","author":"Smith","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R42-4-20210213","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"R43-4-20210213","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/ehm.09.34","article-title":"Prognostic tools in follicular lymphomas","volume":"2","author":"Luminari","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"R44-4-20210213","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12185-010-0674-x","article-title":"Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?","volume":"92","author":"Solal-C\u00e9ligny","year":"2010","journal-title":"Int J Hematol"},{"key":"R45-4-20210213","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"R46-4-20210213","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"key":"R47-4-20210213","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","article-title":"Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response","volume":"97","author":"J\u00e4ger","year":"2012","journal-title":"Haematologica"},{"key":"R48-4-20210213","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/10428190701809156","article-title":"Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab","volume":"49","author":"Ngo","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R49-4-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/10428194.2012.691482","article-title":"Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi\/Grupo de Estudos em Mol\u00e9stias Onco-Hematol\u00f3gicas retrospective study","volume":"54","author":"Carella","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R50-4-20210213","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"key":"R51-4-20210213","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2013-12-543314","article-title":"Is rituximab one for all ages and each sex?","volume":"123","author":"Habermann","year":"2014","journal-title":"Blood"},{"key":"R52-4-20210213","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/sj.onc.1208954","article-title":"Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis","volume":"24","author":"Vega","year":"2005","journal-title":"Oncogene"},{"key":"R53-4-20210213","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4049\/jimmunol.175.4.2174","article-title":"Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin\u2019s lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively","volume":"175","author":"Vega","year":"2005","journal-title":"J Immunol"},{"key":"R54-4-20210213","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/10428194.2010.531408","article-title":"A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells","volume":"52","author":"Vega","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R55-4-20210213","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2007-02-076075","article-title":"Cooperation of the proapoptotic receptor agonist rhApo2L\/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts","volume":"110","author":"Daniel","year":"2007","journal-title":"Blood"},{"key":"R56-4-20210213","first-page":"1688","article-title":"Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer","volume":"7","author":"Fisher","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R57-4-20210213","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","article-title":"BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis","volume":"50","author":"Bukhari","year":"2011","journal-title":"Rheumatology (Oxford"},{"key":"R58-4-20210213","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-07-0680","article-title":"Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20","volume":"13","author":"Maddipatla","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T08:50:27Z","timestamp":1692607827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201702000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000262","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}